<--- Back to Details
First PageDocument Content
Gynaecological cancer / Papillomavirus / Pathology / Histopathology / Carcinoma in situ / Lobular carcinoma / Medi-Cal / Breast cancer / Atypical ductal hyperplasia / Medicine / Oncology / Carcinoma
Date: 2012-12-31 16:16:47
Gynaecological cancer
Papillomavirus
Pathology
Histopathology
Carcinoma in situ
Lobular carcinoma
Medi-Cal
Breast cancer
Atypical ductal hyperplasia
Medicine
Oncology
Carcinoma

Every Woman Counts Recipient Eligibility Form

Add to Reading List

Source URL: files.medi-cal.ca.gov

Download Document from Source Website

File Size: 327,05 KB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document